Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study.

Daniela PuglieseGiuseppe PriviteraFederica CrispinoNicolò MezzinaFabiana CastiglioneGionata FiorinoLucrezia LaterzaAnna Viola Lorenzo BertaniFlavio CaprioliMaria CappelloBrigida BarberioChiara RicciPaola Balestrieri Marco DapernoDario PluchinoFernando RizzelloMaria Lia ScribanoRenato SablichLuca PastorelliFrancesco MangusoAngela VariolaAntonio Di SarioLaurino GrossiAlessandro Armuzzinull null

Published in: Alimentary pharmacology & therapeutics (2022)

Vedolizumab can be considered a safe option in elderly IBD patients. Its effectiveness in elderly UC patients may be reduced, while no age-dependent effect on effectiveness was observed in CD.

Keyphrases

end stage renal disease
patients with inflammatory bowel disease
ejection fraction
newly diagnosed
chronic kidney disease
randomized controlled trial
systematic review
middle aged
peritoneal dialysis
prognostic factors
ulcerative colitis
community dwelling